Precipio Diagnostics has reported a record second-quarter revenue of $7.0 million, representing a 22.8% increase from the same period last year. The company returned to positive adjusted EBITDA and generated $700,000 in operating cash flow.
The strong quarterly performance was driven by growth in both pathology and product revenue. Pathology revenue rose to $6.1 million, while product revenue increased to $900,000, accounting for 12.9% of total quarterly sales.
Revenue Growth
The company's revenue growth aligns with analyst expectations of sales growth in the current year and a return to profitability. Precipio's market capitalization is $42.84 million, with a total return of 62.6% over the past year.
The company maintains a healthy gross profit margin of 44.1%, although its stock is currently trading slightly above its Fair Value of $23.25. Precipio shares closed the regular session at $23.9, up 1.7% from the previous close.
Business Outlook
Management expects continued revenue growth in the second half of 2026, with a focus on partnerships with major distributors and tailoring its sales approach to each one. The company has added new distributor representatives and identified qualified customers, and its Rapid AML Panel has shown growing interest.